Ceritinib
Back to searchMolecule Structure
Scientific Name
Ceritinib
Description of the Drug
Ceritinib is an antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09063
http://www.drugbank.ca/drugs/DB09063
Brand Name(s)
Zykadia
Company Owner(s)
Novartis Pharmaceuticals Corp
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
EML4-ALK | CHIMERIC PROTEIN | INHIBITOR | CHEMBL3883330 |
ALK tyrosine kinase receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL4247 |
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | CHIMERIC PROTEIN | INHIBITOR | CHEMBL2111387 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL1014329 | |
Human Metabolome Database | HMDB0249821 | |
DrugBank | DB09063 | |
PubChem: Thomson Pharma | 136885241 | |
PubChem | 57379345 | |
LINCS | LSM-36374 | |
Nikkaji | J3.252.917H | |
PDBe | 4MK | |
BindingDB | 50436850 | |
EPA CompTox Dashboard | DTXSID10725373 | |
DrugCentral | 4866 | |
Brenda | 255717 | |
ChemicalBook | CB82652832 | |
Guide to Pharmacology | 7397 | |
rxnorm | ZYKADIA | CERITINIB |
ChEBI | 78432 | |
ZINC | ZINC000096272772 |